Novel Sensitizing Agents for Therapeutic Anti EGFR Antibodies

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents an in-depth description of sensitizers to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs or other sensitizers. It gives an insight into the landscape of anti-EGFR based cancer treatment, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. The book offers pertinent basic science information on strategies used for the rational design and discovery of novel sensitizing agents, and, in addition, translational studies involving pre-clinical and clinical design and execution with these novel agents. It covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on EGFR blockage resistance, as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new anticancer sensitizers for anti-EGFR drug resistance. This book is an indispensable resource for cancer researchers, medicinal chemists, and other biomedical scientists involved in the development of new therapeutic agents to overcome resistance to anti-EGFR treatments. Presents detailed description of history, chemistry, mechanism of action, structure-function relationships, pharmacology, side effects, dosing, and formulation of new sensitizers to anti-EGFR antibodies Provides molecular structures for all novel anticancer drugs and strategies to overcome resistance of anti-EGFR antibodies Encompasses up-to-date information on the cancer drug discovery process, including new research tools, tumor-targeting strategies, and fundamental concepts in the emerging areas of precision medicine

Produk Detail:

  • Author : Shi Hu
  • Publisher : Academic Press
  • Pages : 300 pages
  • ISBN : 9780128215845
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKNovel Sensitizing Agents for Therapeutic Anti EGFR Antibodies

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
  • Author : Shi Hu
  • Publisher : Academic Press
  • Release : 15 March 2021
GET THIS BOOKNovel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents an in-depth description of sensitizers to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs or other sensitizers. It gives an insight into the landscape of anti-EGFR based cancer treatment, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. The book offers pertinent basic science information on strategies used for the rational design and discovery of novel sensitizing agents, and, in addition,

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 21 November 2018
GET THIS BOOKProtein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic,

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Dong-hua Yang
  • Publisher : Cancer Sensitizing Agents for
  • Release : 15 November 2018
GET THIS BOOKProtein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, Volume Four in the Cancer Sensitizing Agents for Chemotherapy Series focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and

Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy

Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
  • Author : Benjamin Bonavida
  • Publisher : Springer Science & Business Media
  • Release : 31 July 2008
GET THIS BOOKSensitization of Cancer Cells for Chemo/Immuno/Radio-therapy

This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.

Improving the Therapeutic Ratio in Head and Neck Cancer

Improving the Therapeutic Ratio in Head and Neck Cancer
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 04 October 2019
GET THIS BOOKImproving the Therapeutic Ratio in Head and Neck Cancer

Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic. The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to

Gunderson & Tepper’s Clinical Radiation Oncology, E-Book

Gunderson & Tepper’s Clinical Radiation Oncology, E-Book
  • Author : Joel E. Tepper
  • Publisher : Elsevier Health Sciences
  • Release : 06 December 2019
GET THIS BOOKGunderson & Tepper’s Clinical Radiation Oncology, E-Book

A comprehensive, multidisciplinary resource for the entire radiation oncology team, Gunderson & Tepper’s Clinical Radiation Oncology, 5th Edition, thoroughly covers all aspects of this complex and dynamic field. Concise, templated chapters cover the basic biology of oncologic disease processes as well as updated treatment algorithms, the latest clinical guidelines, and state-of-the-art techniques and modalities. More than 1,000 images—detailed anatomy drawings, radiographic images, and more—provide outstanding visual support for every area of the text. Divides content into three distinct sections

Novel Therapies in Head and Neck Cancer: Beyond the Horizon

Novel Therapies in Head and Neck Cancer: Beyond the Horizon
  • Author : Maie A. St. John,No hee Park
  • Publisher : Academic Press
  • Release : 29 June 2020
GET THIS BOOKNovel Therapies in Head and Neck Cancer: Beyond the Horizon

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine

Is the Recent Burst of Therapeutic Anti-Tumor Antibodies the Tip of an Iceberg?

Is the Recent Burst of Therapeutic Anti-Tumor Antibodies the Tip of an Iceberg?
  • Author : Leonor Kremer,Jose A. Garcia-Sanz
  • Publisher : Frontiers Media SA
  • Release : 27 March 2018
GET THIS BOOKIs the Recent Burst of Therapeutic Anti-Tumor Antibodies the Tip of an Iceberg?

The high effectiveness of antibodies as anti-tumor therapeutic agents has led to a burst of research aiming to increase their therapeutic applications by the use of antibodies against new targets, new antibody formats or new combinations. In this e-book we present relevant research depicting the current efforts in the field.

Noble and Precious Metals

Noble and Precious Metals
  • Author : Mohindar Seehra,Alan Bristow
  • Publisher : BoD – Books on Demand
  • Release : 04 July 2018
GET THIS BOOKNoble and Precious Metals

The use of copper, silver, gold and platinum in jewelry as a measure of wealth is well known. This book contains 19 chapters written by international authors on other uses and applications of noble and precious metals (copper, silver, gold, platinum, palladium, iridium, osmium, rhodium, ruthenium, and rhenium). The topics covered include surface-enhanced Raman scattering, quantum dots, synthesis and properties of nanostructures, and its applications in the diverse fields such as high-tech engineering, nanotechnology, catalysis, and biomedical applications. The basis for

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Immunotherapeutic Antibodies in Cancer
  • Author : Benjamin Bonavida
  • Publisher : Springer Science & Business Media
  • Release : 04 August 2013
GET THIS BOOKResistance to Immunotherapeutic Antibodies in Cancer

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can

Role of Nutraceuticals in Cancer Chemosensitization

Role of Nutraceuticals in Cancer Chemosensitization
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 18 October 2017
GET THIS BOOKRole of Nutraceuticals in Cancer Chemosensitization

Role of Nutraceuticals in Chemoresistance to Cancer, Volume Two, focuses on nutraceuticals, the compounds derived from natural sources, which are usually multi-targeted as a means to overcome chemoresistance. This book discusses the role of several compounds related to nutraceuticals and chemoresistance, such as curcumin, resveratrol, indole 3-carbinol, tocotrienols, ursolic acid, fisetin, celastrol, gambogic, butein, catechins and silymarin. It is a valuable resource for cancer researchers, oncologists and members of several areas of the biomedical field who are interested in understanding

Clinical Radiation Oncology E-Book

Clinical Radiation Oncology E-Book
  • Author : Leonard L. Gunderson,Joel E. Tepper
  • Publisher : Elsevier Health Sciences
  • Release : 16 June 2015
GET THIS BOOKClinical Radiation Oncology E-Book

Perfect for radiation oncology physicians and residents needing a multidisciplinary, treatment-focused resource, this updated edition continues to provide the latest knowledge in this consistently growing field. Not only will you broaden your understanding of the basic biology of disease processes, you'll also access updated treatment algorithms, information on techniques, and state-of-the-art modalities. The consistent and concise format provides just the right amount of information, making Clinical Radiation Oncology a welcome resource for use by the entire radiation oncology team. Content

New Trends in Cancer for the 21st Century

New Trends in Cancer for the 21st Century
  • Author : International Symposium on Cancer "New Trends in Cancer for the 21st Century"
  • Publisher : Springer Science & Business Media
  • Release : 21 June 2021
GET THIS BOOKNew Trends in Cancer for the 21st Century

It is difficult to imagine anyone who has not heard of cancer. This disease can affect families, friends or any one of us at any time in our lives. Every year nearly 3 million Europeans are diagnosed with cancer, leading to around 800,000 deaths per year. These deaths occur not only in aging populations, but also in children and adults who are in the most active period of their lives. This represents a tremendous problem that cannot be ignored by politicians or

Targeted Radionuclide Tumor Therapy

Targeted Radionuclide Tumor Therapy
  • Author : Torgny Stigbrand,Jorgen Carlsson,Gregory P. Adams
  • Publisher : Springer Science & Business Media
  • Release : 01 September 2008
GET THIS BOOKTargeted Radionuclide Tumor Therapy

The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable